Svoboda | Graniru | BBC Russia | Golosameriki | Facebook
BBC Russian Subscribe
Spotlight

Immunology

Latest News
July 9th 2024

Exercise Therapy Can Reduce Symptoms, Disease Activity in Axial Spondyloarthritis

July 3rd 2024

Patient-Reported Pain Improvement Linked With Remission in Rheumatoid Arthritis

July 1st 2024

Obesity Linked to Worse Patient-Reported Outcomes in Rheumatoid Arthritis

June 29th 2024

Preexisting Structural Damage, Inflammation Linked With Radiographic Progression in Patients Treated for AxSpA

June 28th 2024

Bimekizumab Shows Long-Term Efficacy in Nonradiographic AxSpA, Ankylosing Spondylitis

More News

Back pain due to spondyloarthritis- fizkes - stock.adobe.com
June 22nd 2024

AxSpA Treatment Intensification in Practice Linked With Higher ASDAS Cutoff Than Recommended

Rose McNulty
In the clinical practice setting, intensifying treatment for axial spondyloarthritis (axSpA) is associated with a higher Ankylosing Spondylitis Disease Activity Score (ASDAS) cutoff value than recommended, new research found.
Efgartigimod alfa and hyaluronidase is now FDA approved for the treatment of adults with CIDP. | Image credit: wladimir1804 - stock.adobe.com
June 21st 2024

FDA Approves Efgartigimod Alfa and Hyaluronidase for CIDP

Rose McNulty
The FDA today approved efgartigimod alfa and hyaluronidase-qvfc for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Sarilumab FDA Approved for Active Polyarticular Juvenile Idiopathic Arthritis
June 11th 2024

Sarilumab FDA Approved for Active Polyarticular Juvenile Idiopathic Arthritis

Rose McNulty
The approval brings a new treatment option to pediatric patients with polyarticular juvenile idiopathic arthritis, which is a form of arthritis affecting multiple joints at the same time.
Woman with back pain | Image credit: vectorfusionart - stock.adobe.com
June 7th 2024

Study Suggests TNF Inhibitor Use Is Cardioprotective in Radiographic Axial Spondyloarthritis

Rose McNulty
Tumor necrosis factor (TNF) inhibitor use was associated with a lower risk of cardiovascular outcomes in patients with radiographic axial spondyloarthritis in a recent study.
Woman sleeping next to alarm clock | Image credit: stokkete - stock.adobe.com
May 31st 2024

Pain Linked With Poor Sleep Quality, Comorbidities in RA, PsA

Rose McNulty
Among patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), intense pain symptoms were associated with poor sleep, fibromyalgia, depression, and sleep apnea.
Blood analysis | Image credit: Parilov-stock.adobe.com
May 31st 2024

Novel Serum Biomarkers Show Potential for Diagnosing, Monitoring Axial Spondyloarthritis

Rose McNulty
A recent review highlighted several candidate biomarkers for diagnosing axial spondyloarthritis associated with inflammatory bowel disease in early phases.
Concept of hidradenitis suppurativa | Image credit: syahrir - stock.adobe.com
May 24th 2024

Bimekizumab Elicits Clinically Meaningful Responses in Moderate to Severe Hidradenitis Suppurativa

Rose McNulty
Newly published findings from the pivotal phase 3 BE HEARD I and BE HEARD II trials demonstrated that bimekizumab was well tolerated and produced clinically meaningful responses in patients with moderate to severe hidradenitis suppurativa.
Drug costs | Image credit: nikitos - stock.adobe.com
May 20th 2024

IQVIA Report Highlights Shifts in Medicine Use, Spending Across Therapy Areas

Rose McNulty
Areas of focus in the annual report included health system utilization and recovery from the pandemic, patterns of medicine use, drug pricing, and patient out-of-pocket costs.
Document with denied - G_stockerthailand - stock.adobe.com
May 10th 2024

Research Shows Prior Authorization Denials Delay Critical Immunology Care

Giuliana Grossi
Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Young Woman Sitting | Image Credit: Bungon - stock.adobe.com
May 3rd 2024

Bimekizumab Shows Promising 52-Week Safety and Efficacy in Psoriatic Arthritis

Giuliana Grossi
Promising results presented at the Academy of Managed Care Pharmacy 2024 annual meeting support the safety and efficacy of bimekizumab treatment in patients with active psoriatic arthritis who had previously shown inadequate response or intolerance to tumor necrosis factor inhibitors.
Man Feeling Back Pain | Image Credit: Mantinov - stock.adobe.com
April 30th 2024

Bimekizumab Shows Sustained Efficacy in Treating Axial Spondyloarthritis for 52 Weeks

Giuliana Grossi
Results from a study presented at the Academy of Managed Care Pharmacy 2024 annual meeting demonstrated sustained efficacy of bimekizumab compared with placebo in patients with non-radiographic and radiographic axial spondyloarthritis (axSpA) at week 52.
Brain illustration in blue and pink | Image credit: jolygon - stock.adobe.com.jpg
April 17th 2024

Cognitive Impairment Screening in the Clinic for Patients With SLE

Laura Joszt, MA
Screening for cognitive impairment among patients with systemic lupus erythematosus (SLE) can be challenging; however, some shorter assessments have shown promise for use in the clinical setting.
White plastic bottle with medical pills | Image Credit: encierro - stock.adobe.com
April 12th 2024

NSAIDs vs bDMARDs: Sex Disparities in Treatment Initiation for Axial Spondyloarthritis

Giuliana Grossi
New research examining treatment initiation patterns among patients with axial spondyloarthritis revealed significant sex-based disparities, shedding light on the process from diagnosis to therapeutic intervention.
Woman sitting on bed with back pain illustrated by a highlighted spine | Image credit: WavebreakMediaMicro - stock.adobe.com
April 12th 2024

Radiographic Progression Low for High-Risk Patients With axSpA on Both Secukinumab and an Adalimumab Biosimilar

Kimberly Rath, PharmD
Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar.
Hand with psoriatic arthritis | Image credit: Iri-s - stock.adobe.com.jpg
April 4th 2024

Indirect Comparison Finds Bimekizumab More Effective Than Guselkumab in Psoriatic Arthritis

Laura Joszt, MA
Patients included in the analysis had psoriatic arthritis and had either not been treated with biologic disease-modifying antirheumatic drugs or had an inadequate response or an intolerance to tumor necrosis factor inhibitors.
Wooden blocks spelling biosimilar | Image credit: lexiconimages - stock.adobe.com
March 29th 2024

Data Support Safety, Efficacy of Biosimilar-to-Biosimilar Switching

Laura Joszt, MA
The majority of studies evaluating biosimilar-to-biosimilar switching were for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.
Man holding knee with knee pain | Image credit: wavebreak3 - stock.adobe.com
March 22nd 2024

Psychosocial Factors Increase Likelihood of Joint Pain in Psoriatic Arthritis

Laura Joszt, MA
A history of depression was the most predictive factor for developing persistent joint pain among patients with psoriatic arthritis.
Young black guy having heart attack, holding his chest - Prostock-studio - stock.adobe.com
March 19th 2024

Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study

Giuliana Grossi
Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.
Blood testing | Image credit: angellodeco - stock.adobe.com
March 15th 2024

Use of Recommended Tests Before Starting Immunomodulatory Agents for Chronic Inflammatory Skin Diseases Varies

Rose McNulty
A recent study found significant variation in the use of recommended laboratory tests ahead of immunomodulatory treatment in patients with chronic inflammatory skin diseases, with less than 60% of patients in the US receiving recommended pretreatment testing.
Health insurance blocks | Image Credit: REDPIXEL - stock.adobe.com
March 13th 2024

New Study Links Social Factors to Hidradenitis Suppurativa Severity

Giuliana Grossi
Research presented at the American Academy of Dermatology Annual Meeting 2024 explored the impact of social determinants of health on hidradenitis suppurativa severity.
Healthy foods | Image credit: Rodica Ciorba - stock.adobe.com
March 8th 2024

Dietary Interventions Reduce CVD Risk in RA and SpA

Laura Joszt, MA
While dietary interventions do not significantly change the body composition of patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA), they can reduce the risk of cardiovascular disease (CVD).
Health care concept meaning Hidradenitis suppurativa with inscription on the page | Image Credit: Yurii Kibalnik - stock.adobe.com
March 6th 2024

Authors Review Emerging Therapeutic Targets for Hidradenitis Suppurativa

Giuliana Grossi
Despite its impact on patient quality of life, hidradenitis suppurativa (HS) remains underdiagnosed and undertreated; authors outline what's being discovered within the treatment landscape.
Inflammatory bowel disease - Vitalii Vodolazskyi - stock.adobe.com.jpg
February 26th 2024

Psoriasis Severity Tied to Increased Risk of Inflammatory Bowel Disease

Giuliana Grossi
A recent study identified a significant association between psoriasis and inflammatory bowel disease. This link also applied to IBD subtypes: Crohn disease and ulcerative colitis.
Epstein-Barr virus | Image: Dr Microbe
February 23rd 2024

As FDA Filing Approaches for Tab-Cel in EBV+ PTLD, Decades of Science Bear Fruit

Mary Caffrey
Approved in Europe, tabelecleucel may soon be considered by FDA to treat patients who develop Epstein-Barr virus following a transplant, which then triggers a type of deadly lymphoma that may not respond to traditional therapy. Tab-cel, an allogeneic T-cell therapy, comes 30 years after the discovery that T cells might offer hope, followed by decades of research on how to harness them without the side effects.
Woman with psoriasis | Andrey Popov - stock.adobe.com
February 20th 2024

From Psoriasis to PsA: Study Identifies Predictive Factors for Development

Giuliana Grossi
Findings reveal an increased risk of psoriatic arthritis (PsA) among female patients with severe skin psoriasis who have nail involvement and require oral systemic therapy for their condition.
COVID-19 Vaccine Bottle With Syringe | image credit: myskin - stock.adobe.com
December 31st 2023

Patients With RA Receiving DMARDs Have Reduced COVID-19 Vaccine Immune Responses, Study Finds

Kyle Munz
A cross-sectional study finds that patients with rheumatoid arthritis receiving disease-modifying antirheumatic drugs (DMARDs) exhibit a reduced immune response to the COVID-19 vaccine compared with controls.
Man With Lupus Erythematosus | image credit: velimir - stock.adobe.com
December 27th 2023

Afimetoran Shown to Be Safe, Well-Tolerated for Patients With Cutaneous Lupus Erythematosus

Tim Smith
This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with cutaneous lupus erythematosus (CLE).
Woman Enduring Rheumatoid Arthritis | image credit: doucefleur - stock.adobe.com
December 23rd 2023

Training Initiative for Management of Rheumatoid Arthritis Shows Promise in Native American Communities

Tim Smith
This new program was designed to be a scalable model for the formulation of similar initiatives in communities known to have limited access to specialized care for rheumatic conditions.
Rheumatoid Arthritis Flare | image credit: doucefleur - stock.adobe.com
December 8th 2023

Patients With RA in Remission Withdrawing From TNF Inhibition Show Flare Increases

Tim Smith
New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
Autoimmune Thyroid Disease Model | image credit: Jo Panuwat D - stock.adobe.com
November 28th 2023

Disease-Modifying Antirheumatic Drugs Linked to Decreased Risk for Autoimmune Thyroid Disease

Kyle Munz
A nationwide cohort study linked biologic disease-modifying antirheumatic drugs with decreased risks for the onset of autoimmune thyroid disease in patients with rheumatoid arthritis.
12>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo